Baugh & Associates’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $9.43M | Sell |
37,494
-2,831
| -7% | -$609K | 4.17% | 7 |
|
|
2026
Q1 | $8.77M | Sell |
40,325
-186
| -0.5% | -$41.3K | 3.79% | 7 |
|
|
2025
Q4 | $8.65M | Sell |
40,511
-1,251
| -3% | -$285K | 4.25% | 6 |
|
|
2025
Q3 | $8.91M | Sell |
41,762
-981
| -2% | -$200K | 4.43% | 8 |
|
|
2025
Q2 | $7.35M | Sell |
42,743
-2,214
| -5% | -$411K | 3.83% | 9 |
|
|
2025
Q1 | $9.06M | Sell |
44,957
-219
| -0.5% | -$42.6K | 4.59% | 5 |
|
|
2024
Q4 | $7.77M | Buy |
45,176
+816
| +2% | +$150K | 4.03% | 9 |
|
|
2024
Q3 | $8.53M | Buy |
44,360
+390
| +0.9% | +$72.8K | 4.39% | 6 |
|
|
2024
Q2 | $7.9M | Sell |
43,970
-2,236
| -5% | -$370K | 4.1% | 6 |
|
|
2024
Q1 | $8.41M | Sell |
46,206
-33
| -0.1% | -$5.69K | 4.48% | 6 |
|
|
2023
Q4 | $7.17M | Sell |
46,239
-636
| -1% | -$92.7K | 4.12% | 6 |
|
|
2023
Q3 | $6.99M | Sell |
46,875
-136
| -0.3% | -$20K | 4.37% | 5 |
|
|
2023
Q2 | $6.33M | Buy |
47,011
+685
| +1% | +$100K | 3.81% | 6 |
|
|
2023
Q1 | $7.51M | Sell |
46,326
-966
| -2% | -$148K | 4.8% | 5 |
|
|
2022
Q4 | $7.64M | Sell |
47,292
-12
| -0% | -$1.84K | 4.95% | 4 |
|
|
2022
Q3 | $6.35M | Sell |
47,304
-17
| -0% | -$2.44K | 4.49% | 6 |
|
|
2022
Q2 | $7.25M | Sell |
47,321
-525
| -1% | -$80.2K | 4.88% | 3 |
|
|
2022
Q1 | $7.76M | Sell |
47,846
-230
| -0.5% | -$33.4K | 4.56% | 3 |
|
|
2021
Q4 | $6.51M | Buy |
48,076
+369
| +0.8% | +$43.6K | 3.6% | 10 |
|
|
2021
Q3 | $5.15M | Sell |
47,707
-4
| -0% | -$457 | 3.15% | 11 |
|
|
2021
Q2 | $5.37M | Sell |
47,711
-576
| -1% | -$64.9K | 3.33% | 10 |
|
|
2021
Q1 | $5.23M | Buy |
48,287
+159
| +0.3% | +$17K | 3.45% | 10 |
|
|
2020
Q4 | $5.16M | Buy |
48,128
+538
| +1% | +$51.7K | 3.68% | 7 |
|
|
2020
Q3 | $4.17M | Sell |
47,590
-825
| -2% | -$77.7K | 3.27% | 9 |
|
|
2020
Q2 | $4.75M | Buy |
48,415
+976
| +2% | +$85.9K | 3.79% | 8 |
|
|
2020
Q1 | $3.61M | Sell |
47,439
-504
| -1% | -$42.9K | 3.49% | 8 |
|
|
2019
Q4 | $4.25M | Sell |
47,943
-450
| -0.9% | -$37.4K | 3.1% | 11 |
|
|
2019
Q3 | $3.66M | Buy |
48,393
+255
| +0.5% | +$17.5K | 2.84% | 17 |
|
|
2019
Q2 | $3.5M | Buy |
48,138
+6,858
| +17% | +$539K | 2.77% | 19 |
|
|
2019
Q1 | $3.33M | Sell |
41,280
-238
| -0.6% | -$19.5K | 2.67% | 21 |
|
|
2018
Q4 | $3.83M | Sell |
41,518
-60
| -0.1% | -$5.28K | 3.3% | 7 |
|
|
2018
Q3 | $3.93M | Buy |
41,578
+1,264
| +3% | +$120K | 3.14% | 10 |
|
|
2018
Q2 | $3.73M | Sell |
40,314
-1,631
| -4% | -$159K | 3.26% | 6 |
|
|
2018
Q1 | $3.97M | Sell |
41,945
-355
| -0.8% | -$39K | 3.2% | 8 |
|
|
2017
Q4 | $4.09M | Buy |
+42,300
| New | +$3.99M | 3.45% | 7 |
|
Other funds holding ABBV
ECSS
ATO
Baugh & Associates's ABBV Position: Q2 2026 in Review
Baugh & Associates reduced its AbbVie (ABBV) stake by 7% in Q2 2026, selling an estimated $609K and leaving 37,494 shares worth $9.43M. The position accounts for 4.17% of the portfolio, ranked #7.
Baugh & Associates first reported a position in ABBV in Q4 2017 and has held it in 35 quarters since. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Baugh & Associates held 37,494 shares of AbbVie worth $9.43M as of Q2 2026.
- Baugh & Associates sold 2,831 AbbVie shares in Q2 2026, an estimated $609K.
- AbbVie made up 4.17% of Baugh & Associates's portfolio in Q2 2026, its #7 holding.
- Baugh & Associates first reported a position in AbbVie in Q4 2017 and has held it in 35 quarters since.
- 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Baugh & Associates's 13F filing for Q2 2026, filed 13 Jul 2026.